Novo Nordisk’s global head of business development, John McDonald, is seeking partnerships in biotech companies focusing on diabetes and obesity. The company’s dealmaking activity is driven by the need to replace revenue from expiring patents, with a focus on acquiring assets in therapeutic areas like diabetes, obesity, and cardiovascular disease. Novo Nordisk is willing to pay more for high-demand assets and is open to various types of drugs. The company prefers partnerships over acquisitions to retain talent. They have made significant acquisitions, like Dicerna Pharma, and are open to partnering with early-stage companies to drive innovation in the biopharmaceutical industry.
Source link
At BIO, Novo Nordisk’s Top Dealmaker Talks M&A Strategy and What’s Next After GLP-1s
